Company Filing History:
Years Active: 2014-2016
Title: Kenneth Kolinsky: Innovator in Combination Therapy for Proliferative Disorders
Introduction
Kenneth Kolinsky is a notable inventor based in Bloomingdale, NJ (US). He has made significant contributions to the field of medicine, particularly in the area of combination therapies for proliferative disorders. With a total of 4 patents to his name, Kolinsky's work has the potential to impact the treatment of various cancers.
Latest Patents
Kolinsky's latest patents focus on innovative combination therapies aimed at treating proliferative diseases. One of his notable inventions is a combination therapy that utilizes a b-Raf inhibitor and an MDM2 inhibitor. This therapy is designed to address proliferative disorders effectively. Another significant patent involves a combination therapy that includes propane-1-sulfonic acid and an interferon, specifically targeting solid tumors such as colorectal cancer, melanoma, and thyroid cancer. This therapy is particularly relevant for patients with melanoma containing the V600E b-Raf mutation, utilizing peginterferon alfa-2a as part of the treatment regimen.
Career Highlights
Throughout his career, Kenneth Kolinsky has worked with prominent companies in the pharmaceutical industry. He has been associated with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG, where he has contributed to the development of innovative therapies. His work has been instrumental in advancing treatment options for patients suffering from various proliferative disorders.
Collaborations
Kolinsky has collaborated with several professionals in his field, including Brian Higgins and Kathryn Elizabeth Packman. These collaborations have likely enriched his research and contributed to the success of his innovative therapies.
Conclusion
Kenneth Kolinsky's contributions to the field of medicine through his patents and collaborations highlight his commitment to improving treatment options for patients with proliferative disorders. His innovative approaches have the potential to make a significant impact in the medical community.